Akebia Therapeutics (AKBA) Capital Expenditures Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Capital Expenditures Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | 97.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.98% |
| Mar 31, 2026 | 4,061.11% |
| Dec 31, 2025 | 467.69% |
| Sep 30, 2025 | -84.06% |
| Jun 30, 2025 | 111.83% |
| Mar 31, 2025 | -97.06% |
| Dec 31, 2024 | 92.01% |
| Sep 30, 2024 | -94.09% |
| Jun 30, 2024 | 62.13% |
| Mar 31, 2024 | -78.20% |
| Sep 30, 2023 | -19.27% |
| Jun 30, 2023 | 53.49% |
| Mar 31, 2023 | 170.90% |
| Sep 30, 2022 | 140.64% |
| Jun 30, 2022 | -116.86% |
| Mar 31, 2022 | -191.40% |
| Sep 30, 2021 | -36.00% |
| Jun 30, 2021 | -25,245.45% |
| Mar 31, 2021 | -2,858.70% |
| Dec 31, 2020 | 67.06% |